RNA-binding proteins in autoimmunity: From genetics to molecular biology.
Valeria LoddeMatteo FlorisEnrico ZorodduIgnazio Roberto ZarboMaria Laura IddaPublished in: Wiley interdisciplinary reviews. RNA (2023)
Autoimmune diseases (ADs) are chronic pathologies generated by the loss of immune tolerance to the body's own cells and tissues. There is growing recognition that RNA-binding proteins (RBPs) critically govern immunity in healthy and pathological conditions by modulating gene expression post-transcriptionally at all levels: nuclear mRNA splicing and modification, export to the cytoplasm, as well as cytoplasmic mRNA transport, storage, editing, stability, and translation. Despite enormous efforts to identify new therapies for ADs, definitive solutions are not yet available in many instances. Recognizing that many ADs have a strong genetic component, we have explored connections between the molecular biology and the genetics of RBPs in ADs. Here, we review the genetics and molecular biology of RBPs in four major ADs, multiple sclerosis (MS), type 1 diabetes mellitus (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). We anticipate that gaining insights into the genetics and biology of ADs can facilitate the discovery of new therapies. This article is categorized under: RNA in Disease and Development > RNA in Disease.
Keyphrases
- systemic lupus erythematosus
- multiple sclerosis
- gene expression
- rheumatoid arthritis
- disease activity
- crispr cas
- nucleic acid
- induced apoptosis
- mass spectrometry
- signaling pathway
- single molecule
- high throughput
- interstitial lung disease
- radiation therapy
- adipose tissue
- metabolic syndrome
- type diabetes
- locally advanced
- cell proliferation
- cardiovascular disease
- cell cycle arrest
- copy number
- insulin resistance
- systemic sclerosis
- rectal cancer
- pi k akt